Jazz Pharmaceuticals
JAZZ
505 hedge funds and large institutions have $10.2B invested in Jazz Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 111 funds opening new positions, 216 increasing their positions, 127 reducing their positions, and 44 closing their positions.
152% more first-time investments, than exits
New positions opened: 111 | Existing positions closed: 44
70% more repeat investments, than reductions
Existing positions increased: 216 | Existing positions reduced: 127
17% more capital invested
Capital invested by funds: $8.74B → $10.2B (+$1.45B)
15% more funds holding
Funds holding: 441 → 505 (+64)
0.23% less ownership
Funds ownership: 94.4% → 94.17% (-0.23%)
0% less call options, than puts
Call options by funds: $167M | Put options by funds: $167M
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Polaris Capital Management
Boston,
Massachusetts
|
+$224M |
| 2 |
JP Morgan Chase
New York
|
+$171M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$111M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$76.8M |
| 5 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$45.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$71.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$66.5M |
| 3 |
Renaissance Technologies
New York
|
-$59.8M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$50.7M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$42.5M |
JAZZ Hedge Fund Activity: Q2 2021 in Review
505 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2021, worth a combined $10.2B — up 17% from $8.74B a quarter earlier.
Buyers outnumbered sellers: 111 funds opened new JAZZ positions and 44 closed out — a net gain of 67 holders — while 216 added to existing stakes and 127 trimmed.
The largest buyer was Polaris Capital Management, opening a new position worth an estimated $224M. The largest seller was BlackRock, cutting an estimated $71.4M.
- 505 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2021, up from 441 in Q1 2021.
- Funds reported $10.2B of Jazz Pharmaceuticals stock for Q2 2021, up 17% quarter-over-quarter.
- 111 funds opened new Jazz Pharmaceuticals positions in Q2 2021 and 44 closed out, a net change of +67 holders.
- The largest Jazz Pharmaceuticals buyer in Q2 2021 was Polaris Capital Management, an estimated $224M added.
- The largest Jazz Pharmaceuticals seller in Q2 2021 was BlackRock, an estimated $71.4M sold.
Based on aggregated 13F filings for Q2 2021.